Detail page

Knowledge Web

Person

Gerhard Ehninger (1952-)

Arzt

Name	Gerhard Ehninger
Time	1952- (Date of birth and death)
Place	Simmozheim (Geburtsort) Tübingen (Wirkungsort) Dresden (Wirkungsort) Deutschland
Academic degree	Prof. Dr. med.
Profession	Arzt (characteristic profession) Hochschullehrer
Variant	G. Ehninger
Related	Medizinische Klinik und Poliklinik I (Dresden) Universitätsklinikum Carl Gustav Carus Innere Medizin (Thema)
Topic	Personen zu Medizin, Tiermedizin
Further information	ab 1986 Leiter des Knochenmarktransplantationsbereiches an der Medizinischen Klinik Tübingen 1991 Mitbegründer der Deutschen Knochenmarkspenderdatei 1994-2018 Professor für Innere Medizin am Universitätsklinikum der Technischen Universität Dresden
Source	Wikipedia: https://de.wikipedia.org/wiki/Gerhard_Ehninger (Stand: 14.07.2017) Für Überzeugung Grenzen überwinden : Mediziner Gerhard Ehninger kämpft für seine Patienten und forscht zu Therapien : auch im Ruhestand. In: DNN Dresdner Neueste Nachrichten 28.2018, Nr. 18, S. 15
Record type	Person
GND-Identifier	135880483
Record ID	135880483
Involved in show all Prognostic impact of CEBPA mutational subgroups in adult AML Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations Update Hämatologie/Onkologie 2024 Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia Update Hämatologie/Onkologie 2023 Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation Point Mutations in the FLT3-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant KMT2A-PTD Update Hämatologie/Onkologie 2022 Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years Loss-of-function mutations of BCOR are an independent marker of adverse outcomes in intensively treated patients with acute myeloid leukemia Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial Update Hämatologie/Onkologie 2021 Update Hämatologie/Onkologie 2020 Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation Pneumocystis-carinii-Pneumonie bei Immunsuppression : Prophylaxe und Therapie in der Hämatologie, Onkologie und bei Organtransplantation Update Hämatologie/Onkologie 2019 Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT Constitutional SAMD9L mutations cause familial myelodysplastic syndrome and transient monosomy 7 Dresdner Symposium Hämatologie und Onkologie Hämatopoetische Stammzellen : Grundlagen und klinische Einsatzgebiete Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation Transplant outcomes for secondary acute myeloid leukemia: acute leukemia working party of the European Society for Blood and Bone Marrow Transplantation study Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT ABO mismatching and haploidentical hematopoietic stem cell transplantation in acute myeloid leukemia: a report from the ALWP of the EBMT Akute Leukämien : kontinuierlich verbesserte Ergebnisse durch optimierte und neue Therapien Dresdner Symposium Hämatologie und Onkologie Update Hämatologie/Onkologie 2017 What is the outcome of patients with acute leukemia who survive severe acute graft-versus-host disease? Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years—a report from the EBMT acute leukemia working party Allogeneic hematopoietic stem cell transplantation for secondary acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT Dresdner Symposium Hämatologie und Onkologie Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT Hematopoietic stem cells in co-culture with mesenchymal stromal cells - modeling the niche compartments in vitro Karyotype complexity and prognosis in acute myeloid leukemia Update Hämatologie/Onkologie 2016 Dresdner Symposium Hämatologie und Onkologie : 11 Tabellen ; [Dokumentation ausgewählter Beiträge] Hämatopoetische Stammzellen : Grundlagen und klinische Einsatzgebiete ; 50 Tabellen Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide Two cycles of risk-adapted consolidation therapy in patients with acute promyelocytic leukemia. Results from the SAL-AIDA2000 trial Be smart against cancer! A school-based program covering cancer-related risk behavior Abnormal Localization and Accumulation of FLT3-ITD, a Mutant Receptor Tyrosine Kinase Involved in Leukemogenesis Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients – an observational study Be smart against cancer! A school-based program covering cancer-related risk behavior Chlorpromazine Combined with Cidofovir for Treatment of a Patient Suffering from Progressive Multifocal Leukoencephalopathy Dresdner Symposium Hämatologie und Onkologie : 21 Tabellen

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Gerhard Ehninger (1952-)

Prognostic impact of CEBPA mutational subgroups in adult AML

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

Update Hämatologie/Onkologie 2024

Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia

Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia

Update Hämatologie/Onkologie 2023

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial

Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

Point Mutations in the FLT3-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant KMT2A-PTD

Update Hämatologie/Onkologie 2022

Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years

Loss-of-function mutations of BCOR are an independent marker of adverse outcomes in intensively treated patients with acute myeloid leukemia

Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia

Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia

Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results

Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial

Update Hämatologie/Onkologie 2021

Update Hämatologie/Onkologie 2020

Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT

Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT

Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT

Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation

Pneumocystis-carinii-Pneumonie bei Immunsuppression : Prophylaxe und Therapie in der Hämatologie, Onkologie und bei Organtransplantation

Update Hämatologie/Onkologie 2019

Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT

Constitutional SAMD9L mutations cause familial myelodysplastic syndrome and transient monosomy 7

Dresdner Symposium Hämatologie und Onkologie

Hämatopoetische Stammzellen : Grundlagen und klinische Einsatzgebiete

Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients

Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation

Transplant outcomes for secondary acute myeloid leukemia: acute leukemia working party of the European Society for Blood and Bone Marrow Transplantation study

Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT

ABO mismatching and haploidentical hematopoietic stem cell transplantation in acute myeloid leukemia: a report from the ALWP of the EBMT

Akute Leukämien : kontinuierlich verbesserte Ergebnisse durch optimierte und neue Therapien

Dresdner Symposium Hämatologie und Onkologie

Update Hämatologie/Onkologie 2017

What is the outcome of patients with acute leukemia who survive severe acute graft-versus-host disease?

Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study

The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years—a report from the EBMT acute leukemia working party

Allogeneic hematopoietic stem cell transplantation for secondary acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT

Dresdner Symposium Hämatologie und Onkologie

Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT

Hematopoietic stem cells in co-culture with mesenchymal stromal cells - modeling the niche compartments in vitro

Karyotype complexity and prognosis in acute myeloid leukemia

Update Hämatologie/Onkologie 2016

Dresdner Symposium Hämatologie und Onkologie : 11 Tabellen ; [Dokumentation ausgewählter Beiträge]

Hämatopoetische Stammzellen : Grundlagen und klinische Einsatzgebiete ; 50 Tabellen

Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide

Two cycles of risk-adapted consolidation therapy in patients with acute promyelocytic leukemia. Results from the SAL-AIDA2000 trial

Be smart against cancer! A school-based program covering cancer-related risk behavior

Abnormal Localization and Accumulation of FLT3-ITD, a Mutant Receptor Tyrosine Kinase Involved in Leukemogenesis

Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients – an observational study

Be smart against cancer! A school-based program covering cancer-related risk behavior

Chlorpromazine Combined with Cidofovir for Treatment of a Patient Suffering from Progressive Multifocal Leukoencephalopathy

Dresdner Symposium Hämatologie und Onkologie : 21 Tabellen